Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
ViroMissile, Inc.
EMD Serono
Arcus Biosciences, Inc.
Seagen Inc.
Tizona Therapeutics, Inc
NiKang Therapeutics, Inc.
Poseida Therapeutics, Inc.
Baylor College of Medicine
MacroGenics
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Iambic Therapeutics, Inc
SN BioScience
Innate Pharma
GlaxoSmithKline
SystImmune Inc.
AbbVie
Rondo Therapeutics
SillaJen, Inc.
Actym Therapeutics, Inc.
NiKang Therapeutics, Inc.
Sanofi
Nurix Therapeutics, Inc.
GONGCHU Biotechnology Co., Ltd
Exelixis
Jonsson Comprehensive Cancer Center
First Affiliated Hospital of Zhejiang University
University of Virginia
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Monopar Therapeutics
Monopar Therapeutics
Columbia University
Orion Biotechnology Polska Sp. z o.o.
Rutgers, The State University of New Jersey
MacroGenics
Boehringer Ingelheim
Seagen Inc.
Zymeworks BC Inc.
GC Cell Corporation
Sotio Biotech Inc.
Carisma Therapeutics Inc
Acepodia Biotech, Inc.
Jazz Pharmaceuticals
Vincerx Pharma, Inc.
Shanghai PerHum Therapeutics Co., Ltd.
NGM Biopharmaceuticals, Inc
Bayer
Danatlas Pharmaceuticals Co., Ltd
Xencor, Inc.